Covalon Technologies Ltd. to Showcase Breakthrough Surgical Wound Care Product at the American College of Surgeons Clinical Congress

Published: Oct 21, 2011

MISSISSAUGA, ON, Oct. 21, 2011 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced it will be presenting SurgiClear, its new breakthrough surgical wound care product at this year's American College of Surgeons Clinical Congress (ACS), running October 23 to 27, 2011 in San Francisco.

SurgiClear is a clear film dressing with a breakthrough antimicrobial silicone adhesive especially designed to reduce the instances of surgical site infections.

Surgical site infections occur when germs enter the body through the incision site after a surgical procedure. Treating surgical site infections is a costly burden to the healthcare system and can cause serious, and in certain cases, life-threatening complications for patients. According to the Journal of Infection Control and Hospital Epidemiology, treating surgical site infections accounts for up to $10 billion annually in healthcare expenditures in the United States alone.

SurgiClear is the first transparent film dressing that allows clinicians and patients to monitor the healing process of surgical sites while providing effective antimicrobial protection for up to seven days against the leading organisms that cause surgical site infections, with the aid of two antimicrobial compounds infused directly into the silicone adhesive.

"We are extremely excited to showcase SurgiClear at this year's ACS meeting," said Brian Pedlar, Covalon's Chief Executive Officer. "There has been great excitement and interest about SurgiClear from surgeons, and medical device companies who are looking to license breakthrough new products."

To learn more about Covalon's products and services, please visit us at booth 1938 in the San Francisco Moscone Convention Centre from October 23 to 27 or contact Brian Pedlar, CEO Covalon Technologies Ltd. at

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

SOURCE Covalon Technologies Ltd.

Back to news